BIND Therapeutics, Inc. - Product Pipeline Review - 2015

Published: May, 2015 | Pages: 31 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

BIND Therapeutics, Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'BIND Therapeutics, Inc. - Product Pipeline Review - 2015', provides an overview of the BIND Therapeutics, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of BIND Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of BIND Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of BIND Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the BIND Therapeutics, Inc.'s pipeline products

Reason to Buy

- Evaluate BIND Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of BIND Therapeutics, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the BIND Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of BIND Therapeutics, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of BIND Therapeutics, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of BIND Therapeutics, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
BIND Therapeutics, Inc. Snapshot 5
BIND Therapeutics, Inc. Overview 5
Key Information 5
Key Facts 5
BIND Therapeutics, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
BIND Therapeutics, Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
BIND Therapeutics, Inc. - Pipeline Products Glance 10
BIND Therapeutics, Inc. - Clinical Stage Pipeline Products 10
Phase II Products/Combination Treatment Modalities 10
BIND Therapeutics, Inc. - Early Stage Pipeline Products 11
Preclinical Products/Combination Treatment Modalities 11
BIND Therapeutics, Inc. - Drug Profiles 12
docetaxel 12
Product Description 12
Mechanism of Action 12
R&D Progress 12
AZD-2811 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
Small Molecule 1 for Oncology 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
Small Molecule 2 for Oncology 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Small Molecule to Inhibit Kinesin Spindle Protein for Cancer 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Small Molecule to Inhibit PLK1 for Cancer 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
vincristine sulfate 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
BIND Therapeutics, Inc. - Pipeline Analysis 20
BIND Therapeutics, Inc. - Pipeline Products by Target 20
BIND Therapeutics, Inc. - Pipeline Products by Route of Administration 21
BIND Therapeutics, Inc. - Pipeline Products by Molecule Type 22
BIND Therapeutics, Inc. - Pipeline Products by Mechanism of Action 23
BIND Therapeutics, Inc. - Recent Pipeline Updates 24
BIND Therapeutics, Inc. - Dormant Projects 28
BIND Therapeutics, Inc. - Locations And Subsidiaries 29
Head Office 29
Appendix 30
Methodology 30
Coverage 30
Secondary Research 30
Primary Research 30
Expert Panel Validation 30
Contact Us 30
Disclaimer 31

List of Tables

BIND Therapeutics, Inc., Key Information 5
BIND Therapeutics, Inc., Key Facts 5
BIND Therapeutics, Inc. - Pipeline by Indication, 2015 7
BIND Therapeutics, Inc. - Pipeline by Stage of Development, 2015 8
BIND Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015 9
BIND Therapeutics, Inc. - Phase II, 2015 10
BIND Therapeutics, Inc. - Preclinical, 2015 11
BIND Therapeutics, Inc. - Pipeline by Target, 2015 20
BIND Therapeutics, Inc. - Pipeline by Route of Administration, 2015 21
BIND Therapeutics, Inc. - Pipeline by Molecule Type, 2015 22
BIND Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2015 23
BIND Therapeutics, Inc. - Recent Pipeline Updates, 2015 24
BIND Therapeutics, Inc. - Dormant Developmental Projects,2015 28